BriaCell closes $13.8M public offering of units with warrants

BriaCell Therapeutics Corp.

Gross proceeds of ~$13.8M from 3,066,666 units at $4.50/unit, including 399,999 from over-allotment
Each unit consists of one common share (or pre-funded warrant) and one warrant exercisable at $5.25 for five years
Warrants commenced trading on Nasdaq under BCTXZ on April 25, 2025
Net proceeds to be used for working capital, general corporate purposes, and advancing business objectives
ThinkEquity acted as sole book-running manager; offering closed on April 28, 2025

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.